지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2022.7
- 수록면
- 408 - 424 (17page)
- DOI
- 10.3350/cmh.2022.0012
이용수
초록· 키워드
오류제보하기
Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved clinical outcomes. However, functional cure is rarely attainable by current treatment modalities. RNA interference (RNAi) by small-interfering RNA (siRNA) and anti-sense oligonucleotide (ASO) has been studied as a novel treatment strategy for CHB. RNAi targets post-transcriptional messenger RNAs and pregenomic RNAs to reduce hepatitis B virus (HBV) antigen production and viral replication. By reducing viral antigens, host immune reconstitution against HBV may also be attained. Phase I/II trials on siRNAs have demonstrated them to be safe and well-tolerated. siRNA is effective when given in monthly doses with different total number of doses according to different trial design, and can lead to sustainable dose-dependent mean HBsAg reduction by 2?2.5 log. Incidences of HBsAg seroclearance after siRNA therapy have also been reported.
ASOs have also been studied in early phase trials, and a phase Ib study using frequent dosing regimen within 4 weeks could achieve similar HBsAg reduction of 2 log from baseline. Given the established efficacy and safety of nucleos(t) ide analogues (NAs), future RNAi regimens will likely include NA backbone. While the current evidence on RNAi appears promising, it remains undetermined whether the potent HBsAg reduction by RNAi can result in a high rate of HBsAg seroclearance with durability. Data on RNAi from phase IIb/III trials are keenly anticipated.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay
Gut and Liver
2015 .01
-
Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B
Clinical and Molecular Hepatology
2016 .01
-
The role of different viral biomarkers on the management of chronic hepatitis B
Clinical and Molecular Hepatology
2023 .04
-
Efficient and specific gene knockdown by small interfering RNAs for biomedical application
한국실험동물학회 학술발표대회 논문집
2019 .07
-
Improvement of the Accuracy of Hepatitis B Surface Antigen Testing Using a Confirmatory Test
Journal of Laboratory Medicine And Quality Assurance
2021 .01
-
Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance
Clinical and Molecular Hepatology
2021 .01
-
Current Status of Hepatitis B Surface Antigen Neutralization Testing in Korea
Journal of Laboratory Medicine And Quality Assurance
2024 .06
-
Letter regarding “Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation”
Clinical and Molecular Hepatology
2024 .04
-
Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen
Clinical and Molecular Hepatology
2024 .04
-
Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”
Clinical and Molecular Hepatology
2023 .01
-
ELISA for Quantitative Determination of Hepatitis B Virus Surface Antigen
Immune Network
2017 .12
-
Disease Characteristics and Change in Arthritis Activity according to Treatment in Hepatitis B Surface Antigen-positive Rheumatoid Arthritis Patients: a Retrospective Chart Review Study
Journal of Korean Medical Science
2018 .01
-
Toward a Functional Cure for Hepatitis B
Gut and Liver
2024 .07
-
Long-term Hepatitis B Surface Antigen Profile and Seroclearance after Severe Acute Flares of Chronic Hepatitis B
Gut and Liver
2023 .03
-
Management of Antiviral Resistance in Chronic Hepatitis B
Gut and Liver
2017 .01
-
Expression of Hepatocyte Hepatitis B Core Antigen and Hepatitis B Surface Antigen as a Marker in the Management of Chronic Hepatitis B Patients
Gut and Liver
2017 .01
-
New Biomarkers of Chronic Hepatitis B
Gut and Liver
2019 .01
-
Development of a Rapid Automated Fluorescent Lateral Flow Immunoassay to Detect Hepatitis B Surface Antigen (HBsAg), Antibody to HBsAg, and Antibody to Hepatitis C
Annals of Laboratory Medicine
2018 .01
-
A Study on the Trend of Changes in the Positive Rate of Hepatitis B Surface Antigens and Antibodies over the Last 9 Years in One Health Care Center
대한의생명과학회지
2023 .12
이 논문의 저자 정보
최근 본 자료
댓글(0)
0